8-K
filed February 24, 2025, 6:59 PM ET
ticker IDAI
CIK 0001718939
regulatory
confidence high
sentiment neutral
materiality 0.25
T Stamp regains compliance with Nasdaq annual meeting requirement
T Stamp Inc
- Received Nasdaq deficiency letter on Jan 21, 2025 for failing to hold annual meeting within 12 months of fiscal year end.
- Held annual meeting on January 29, 2025 to address the deficiency.
- Nasdaq notified T Stamp on February 21, 2025 that compliance with Listing Rule 5620(a) has been regained.
Machine-readable event card
- schema_version
- secwatch.filing_event.v1
- accession
- 0001718939-25-000043
- form_type
- 8-K
- ticker
- IDAI
- cik
- 0001718939
- company_name
- T Stamp Inc
- filed_at
- 2025-02-24T23:59:59+00:00
- discovered_at
- 2026-05-14T18:03:04.576921+00:00
- generated_at
- 2026-05-26T06:01:38.988349+00:00
- sec_items
- ["8.01"]
- event_type
- regulatory
- sentiment
- neutral
- materiality_score
- 0.25
- calibrated_materiality_score
- 0.25
- confidence
- high
- secwatch_canonical_url
- https://secwatch.observer/filing/0001718939-25-000043
- json_url
- https://secwatch.observer/filing/0001718939-25-000043.json
- markdown_url
- https://secwatch.observer/filing/0001718939-25-000043.md
- text_url
- https://secwatch.observer/filing/0001718939-25-000043.txt
- edgar_index_url
- https://www.sec.gov/Archives/edgar/data/1718939/000171893925000043/0001718939-25-000043-index.htm
- edgar_primary_document_url
- https://www.sec.gov/Archives/edgar/data/1718939/000171893925000043/idai-20250221.htm
- generated_by_model
- deepseek-v4-flash:cloud@v2
- review_status
- machine_generated
- human_reviewed
- false
- corrected
- false
- correction_note
- null
- correction_timestamp
- null
- superseded_by
- null
Comparable filings
CLIR
ClearSign Technologies suspends ATM prospectus supplement for $10.39 million common stock offering; no shares sold
ClearSign Technologies Corp
May 28, 2026, 4:19 PM ET
regulatory
Items 8.01, 9.01
same SEC item: 8.01
same event type: regulatory
similar materiality
Filing page
SEC filing
QNCX
Quince Therapeutics regains Nasdaq listing compliance via equity alternative
Quince Therapeutics, Inc.
May 21, 2026, 5:06 PM ET
regulatory
Items 8.01
same SEC item: 8.01
same event type: regulatory
similar materiality
Filing page
SEC filing
AIRE
reAlpha regains Nasdaq minimum bid price compliance; matter closed
reAlpha Tech Corp.
May 14, 2026, 4:20 PM ET
regulatory
Items 8.01, 9.01
same SEC item: 8.01
same event type: regulatory
similar materiality
Filing page
SEC filing
PDSB
PDS Biotech regains Nasdaq minimum bid price compliance as of June 2, 2026
PDS Biotechnology Corp
June 2, 2026, 3:35 PM ET
regulatory
Items 8.01
same SEC item: 8.01
same event type: regulatory
Filing page
SEC filing
CING
Cingulate receives FDA Complete Response Letter for CTx-1301; no safety/efficacy issues, CMC-only
Cingulate Inc.
June 2, 2026, 8:10 AM ET
regulatory
Items 7.01, 8.01, 9.01
same SEC item: 8.01
same event type: regulatory
Filing page
SEC filing
MNKD
FDA approves Afrezza for pediatric diabetes patients ages 6+
MANNKIND CORP
June 2, 2026, 8:00 AM ET
regulatory
Items 8.01
same SEC item: 8.01
same event type: regulatory
Filing page
SEC filing
VERA
Vera Therapeutics announces FDA alignment on earlier eGFR analysis for atacicept; results expected Q3 2026
Vera Therapeutics, Inc.
June 2, 2026, 7:05 AM ET
regulatory
Items 8.01
same SEC item: 8.01
same event type: regulatory
Filing page
SEC filing
TXNM
TXNM subsidiaries: TNMP rate settlement with $20.5M storm rider, PNM resource plan with 1.65 GW renewables
TXNM ENERGY INC
June 1, 2026, 5:54 PM ET
regulatory
Items 7.01, 8.01, 9.01
same SEC item: 8.01
same event type: regulatory
Filing page
SEC filing
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.